A protein interaction map identifies existing drugs targeting SARS-CoV-2
Abstract Background Severe acute respiratory syndrome coronavirus (SARS-CoV-2), an emerging Betacoronavirus, is the causative agent of COVID-19. Angiotensin converting enzyme 2 (ACE2), being the main cell receptor of SARS-CoV-2, plays a role in the entry of the virus into the cell. Currently, there...
Main Authors: | Claudia Cava, Gloria Bertoli, Isabella Castiglioni |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-09-01
|
Series: | BMC Pharmacology and Toxicology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40360-020-00444-z |
Similar Items
-
Rilpivirine inhibits SARS-CoV-2 protein targets: A potential multi-target drug
by: Fuad Ameen, et al.
Published: (2021-10-01) -
In-silico studies of amentoflavone and its derivatives against sars-cov-2
by: Achmad, A., et al.
Published: (2021) -
Data on the docking of phytoconstituents of betel plant and matcha green tea on SARS-CoV-2
by: Fatimawali, et al.
Published: (2021-06-01) -
Computational investigations of three main drugs and their comparison with synthesized compounds as potent inhibitors of SARS-CoV-2 main protease (Mpro): DFT, QSAR, molecular docking, and in silico toxicity analysis
by: Ranjan K. Mohapatra, et al.
Published: (2021-03-01) -
Magical bullets from an indigenous Indian medicinal plant Tinospora cordifolia: An in silico approach for the antidote of SARS-CoV-2
by: Sampark S. Thakkar, et al.
Published: (2021-03-01)